


[Home](#) [Media](#) [Careers](#) [History](#) [Language](#)
[Corporate Information](#) [Our Businesses](#) [R&D](#) [Therapies](#) [Investor Information](#)
[CSR](#)
[Home](#) > [Corporate Information](#) > [At a Glance](#)

PLAINTIFFS'
TRIAL EXHIBIT
PTX0379

exhibitsticker.com

At a Glance



Cipla is a global pharmaceutical company whose goal is to ensure that no patient shall be denied access to high quality & affordable medicine and support.

Mission:

Cipla's mission is to be a leading **global healthcare company** which uses technology and innovation to meet every day needs of all the patients.



Incorporated
1935



Founder
(1898-1972)
Dr. K.A. Hamied



Employees*
20,000+




Non-Executive Chairman
Dr. Y.K. Hamied



Turnover*
USD 1.78 Billion



Non-Executive Vice-Chairman
Mr. M.K. Hamied



Registered Office

<http://www.cipla.com/en/corporate-information/at-a-glance.html>

1/3

MEDA_APTX03503148

CIP2069

Argentum Pharmaceuticals LLC v. Cipla Ltd.

IPR2017-00807

PTX0379-00001



Cipla Limited, Cipla House, Peninsula Business Park,
Ganpatrao Kadam Marg, Lower Parel, Mumbai
400 013



Listing

Equity Shares: BSE Limited and National Stock Exchange of India Limited

Global Depository Receipts: Luxembourg Stock Exchange



Highlights

Continuous innovation in R & D with 35+ world firsts.

Over 1,000 products across various therapeutic categories, with 60+ dosage forms.

Presence in over 100 countries



Approvals

US FDA, WHO-Geneva, MHRA-UK, TGA-Australia, SUKL-Slovak Republic, APVMA-Australia, MCC-South Africa, PIC-Germany, Danish Medical Agency, ANVISA-Brazil, INVIMA- Colombia, NDA-Uganda, Department of Health-Canada and MOH-Saudi Arabia, among others



Contact

Mumbai Central Office: +91 22 23082891, +91 22 23095521

Peninsula Business Park Office: +91 22

24826000, +91 22 24826701, +91 22 24826300

CORPORATE
INFORMATION[At a Glance](#)[Board of Directors](#)[Partnership](#)[Code of Conduct](#)[Quality](#)[Plants & Capacities](#)OUR
BUSINESSES[Geographies](#)[Strategic Business
Units](#)[Cipla New Ventures](#)

R & D

[Leader in Drug
Delivery](#)[Formulation
Development](#)[API
Development](#)[Regulatory](#)[Platform
Technology](#)[CSR](#)[CSR Report](#)[Palliative Care](#)

THERAPIES

[Cardiovascular](#) [Children's
Health](#)[Dermatology
and
Cosmetology](#)[HIV/AIDS](#) [Hepatitis](#)[Infectious
Diseases &
Critical Care](#)[Neurosciences](#) [Oncology](#)[Ophthalmology](#) [Osteoporosis](#)[Respiratory](#) [Urology](#)[Women's
Health](#) [Devices](#)INVESTOR
INFORMATION[Financial Results](#)[Annual Report and
Chairman's Speech](#)[Conference Call Transcripts](#)[Shareholder Information](#)[Unclaimed Dividend](#)

QUICK LINKS

www.act-c.inwww.breathefree.comwww.carebeyondcure.orgwww.ciplamed.com[Privacy Policy](#)[Disclaimer](#)[Contact Us](#)[Site Map](#)[Caution Notice - "Recruitment](#)

Site by



MAGNON\TBWA

[Fraud"](#)

© Copyright 2016 Cipla Inc. All

rights reserved

